Table 13Olanzapine compared with risperidone: Adverse events

StudyAtypical antipsychoticMean daily doseDizzinessSomnolenceConstipation
Atmaca 2003Olanzapine16 mgNot reportedNot reportedNot reported
Risperidone7 mgNot reportedNot reportedNot reported
Volavka 2002OlanzapineaNot reportedNot reportedNot reported
RisperidoneaNot reportedNot reportedNot reported
Conley 2001Olanzapine12 mg27/189 (14.3%)73/189 (38.6%)
Risperidone5 mg26/188 (13.8%)69/188 (36.7%)
Guerje 1998Olanzapine17 mg3/32 (9%)9/32 (28%)1/32 (3%)
Risperidone7 mg4/33 (12%)20/33 (61%)b6/33 (18%)b
Jeste 2003Olanzapine11 mg10/88 (11%)12/88 (14%)6/88 (7%)
Risperidone2 mg9/87 (10%)12/87 (14%)5/87 (6%)
Pooled result relative risk (95% CI)1.02 (0.68 to 1.54)0.81 (0.49 to 1.36)0.55 (0.08 to 3.62)

Meta-analyses weighted by variance.


Mean daily doses during first 8 weeks were olanzapine 19.6 mg and risperidone 7.9 mg, and during last 6 weeks were olanzapine 30.4 mg and risperidone 11.6 mg.


From: Results

Cover of Drug Class Review: Atypical Antipsychotic Drugs
Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].
McDonagh M, Peterson K, Carson S, et al.
Portland (OR): Oregon Health & Science University; 2010 Jul.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.